Voyager Therapeutics, Inc.
VYGR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $327 | $363 | $234 | $102 |
| - Cash | $71 | $69 | $99 | $117 |
| + Debt | $44 | $20 | $23 | $44 |
| Enterprise Value | $299 | $315 | $158 | $29 |
| Revenue | $80 | $250 | $41 | $37 |
| % Growth | -68% | 511.2% | 9.3% | – |
| Gross Profit | $80 | $158 | -$15 | -$36 |
| % Margin | 100% | 63.1% | -36.3% | -97.2% |
| EBITDA | -$79 | $126 | -$40 | -$68 |
| % Margin | -98.2% | 50.6% | -96.9% | -183% |
| Net Income | -$65 | $132 | -$46 | -$71 |
| % Margin | -81.3% | 52.9% | -113.4% | -190.3% |
| EPS Diluted | -1.13 | 2.97 | -1.21 | -1.75 |
| % Growth | -138% | 345.5% | 30.9% | – |
| Operating Cash Flow | -$15 | $78 | -$13 | -$54 |
| Capital Expenditures | -$4 | -$3 | -$2 | -$2 |
| Free Cash Flow | -$19 | $75 | -$15 | -$55 |